When did Immix Biopharma, Inc. report Q4 2024 earnings?

Immix Biopharma, Inc. (IMMX) reported Q4 2024 earnings on March 24, 2025 before market open.

What were Immix Biopharma, Inc.'s Q4 2024 revenue and EPS?

Immix Biopharma, Inc. reported revenue of $96.3K and eps of $-0.16 for Q4 2024.

Did Immix Biopharma, Inc. beat estimates in Q4 2024?

EPS beat the consensus estimate of $-0.25 by $0.09.

Where can I find Immix Biopharma, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001641172-25-000387) directly on SEC EDGAR. The filing index links above go to sec.gov.

Immix Biopharma, Inc. IMMX Q4 2024 Annual earnings

Reported March 24, 2025 · Before market open

Revenue$96.3K

EPS-$0.16Beat by $0.09

EPS estimate-$0.25

Next report

Aug 14, 2026 (In 2 weeks)

EPS estimate-$0.17

Financials

Q4 2024

Income statement

See full

Operating income-$5.0M+7.2%

Net income-$4.8M+5.5%

EPS (diluted)-$0.16+33.3%

Balance sheet

See full

Cash & equivalents$17.7M+1.0%

Total debt$1.1M—

Total equity$13.3M-19.2%

Total assets$22.9M+15.2%

Cash flow

See full

Operating cash flow-$1.5M+44.9%

CapEx$507.2K+3,749%

Free cash flow-$2.0M+26.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$60.52M-56.1%

Enterprise value$43.91M—

Returns & leverage

See full

Return on equity-145.8%+95.9pp

Debt / equity0.1×—

Current ratio2.3×-3.0×

Versus estimates

Revenue

Q4 2024$96.3K

Diluted EPS

Q1 2026-$0.18Beat by $0.00 Q3 2025-$0.24Miss by $0.05 Q2 2025-$0.22Miss by $0.01 Q1 2025-$0.15Beat by $0.08

Q4 2024-$0.16Beat by $0.09

Q3 2024-$0.24Miss by $0.08

Ask the moment Immix Biopharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Immix Biopharma, Inc. report Q4 2024 earnings?: Immix Biopharma, Inc. (IMMX) reported Q4 2024 earnings on March 24, 2025 before market open.
What were Immix Biopharma, Inc.'s Q4 2024 revenue and EPS?: Immix Biopharma, Inc. reported revenue of $96.3K and eps of $-0.16 for Q4 2024.
Did Immix Biopharma, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.25 by $0.09.
Where can I find Immix Biopharma, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001641172-25-000387) directly on SEC EDGAR. The filing index links above go to sec.gov.